Somaxon Pharmaceuticals — Investor Presentation (October 2006)
29 slides from Somaxon Pharmaceuticals's investor presentation, Oct 31, 2006
Slide 1: Specialty Pharmaceuticals for Psychiatry & Neurology
Specialty Pharmaceuticals for Psychiatry & Neurology NASDAQ: SOMX
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about our business, including results of our clinical trials, potential indications for our product candidates, development timelines, future financial results and events that have not yet occurred. Pharmaceutical devel
Slide 3: Highlights
Highlights Specialty pharmaceuticals focused on psychiatric and neurologic disorders Three in-licensed product candidates with extensive human experience & established safety records Highly differentiated product profiles addressing large markets, including 2 positive Phase 3 trials in insomnia Comp
Slide 4: Pipeline
Pipeline SILENOR(tm) - Insomnia Nalmefene - Impulse Control Disorders Acamprosate Movement Disorders Pre- Clinical Phase 1 Phase 2 Phase 3 Nalmefene - Smoking Cessation
Slide 5: Insomnia Market Growth
Insomnia Market Growth 2001 2002 2003 2004 2005 East 1.3 1.8 2.2 2.7 3.3 Total Dollars Billions $1.3 $1.8 $2.2 $2.7 $3.3 Source: Wolters Kluwer Health
Slide 6: Insomnia Prescription Growth
Insomnia Prescription Growth 2001 2002 2003 2004 2005 Ambien 14.89 19.33 22.14 24.49 24.8 Trazodone 8.43 9.5 10.15 10.84 10.81 Other 5.25 5.66 6.01 6.36 6.47 Sonata 1.56 1.78 1.68 1.58 1.38 Lunesta 0 0 0 0 3.18 Ambien CR 0 0 0 0 0.62 Rozerem 0 0 0 0 0.13 Total Rx Millions 30 36 40 43 47 Source: Wolt
Slide 7: Insomnia Complaints
Insomnia Complaints 70 Million Americans report symptoms of insomnia Somaxon estimates fewer than 10 Million use Rx treatment Sleep in America Poll 2002 Difficulty falling asleep Waking frequently during the night Waking too early Wake feeling unrefreshed 25% 40% 24% 36% Sleep Maintenance 24% 36%
Slide 8: LUNESTA Schedule IV controlled substance warning
LUNESTA has been classified as a Schedule IV controlled substance. Sedative hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. The risk of abuse and dependence increases with the dose and duration of treatment Lunesta
Slide 9: SILENOR (doxepin HCl) for Insomnia
SILENOR(tm)(doxepin HCl) for Insomnia Tricyclic compound approved >35 years as an antidepressant Long term safety record with chronic usage A range of pharmacologic activities at high dosages, while clinically a selective H1 antagonist at very low dosages Believed to promote sleep via H1, not GABA
Slide 10: SILENOR vs GABA acting drugs
"Doxepin HCl is virtually devoid of euphoria as a side effect. Characteristic of this type of compound, doxepin HCl has not been demonstrated to produce the physical tolerance or psychological dependence associated with addictive compounds." SILENOR(tm) vs GABA acting drugs "LUNESTA is a Schedule IV
Slide 11: Daily Dosage (mg)
Daily Dosage (mg) 10 25 50 75 300 Depression Sedation, anticholinergic & other side effects Two issued US patents claiming treatment of insomnia at low dose Additional patent applications on file/in process 1 6 Insomnia SILENOR(tm) Well tolerated 3
Slide 12: Product Differentiation
Product Differentiation Doxepin HCl Silenor(tm) Available Dosage Forms 10-150mg 1,3, (6)mg Product Form Capsules Tablets Indication Depression Insomnia Anticholinergic Yes No Daytime Sedation Yes No Branded/Promoted No Yes Sampled No Yes Patents No Yes Hatch-Waxman Exclusivity No Yes
Slide 13: Wake After Sleep Onset (WASO) - Chronic Insomnia Trial
PBO DXP 3mg DXP 6mg N1 66.7 41.4 36.3 N29 61.8 47.3 41.2 Minutes (mean) Nights p<0.0001 p<0.0001 p=0.0299 p=0.0012 Wake After Sleep Onset (WASO) Phase 3 - Chronic Insomnia PSG Trial Primary Endpoint
Slide 14: Total Sleep Time (TST) - Chronic Insomnia Trial
PBO DXP 3mg DXP 6mg N1 373.8 415.3 420.5 N29 391 408.1 419.1 Nights p<0.0001 p<0.0001 p=0.0262 p=0.0003 Phase 3 - Chronic Insomnia PSG Trial Total Sleep Time (TST) Minutes (mean)
Slide 15: Latency to Persistent Sleep - Chronic Insomnia Trial
PBO DXP 3mg DXP 6mg N1 45 26.7 27.1 N29 31.3 28 24.7 Nights Phase 3 - Chronic Insomnia PSG Trial Latency to Persistent Sleep (LPS) p=0.0018 p=0.0110 p=0.9008 p=0.9989 Minutes (mean)
Slide 16: Sleep Efficiency by Hour - Chronic Insomnia Trial
PBO DXP 3mg DXP 6mg 0 1 0.505 0.62 0.606 2 0.783 0.901 0.914 3 0.848 0.933 0.93 4 0.861 0.909 0.932 5 0.829 0.898 0.901 6 0.807 0.894 0.93 7 0.852 0.888 0.912 8 0.745 0.878 0.884 Phase 3 - Chronic Insomnia PSG Trial Sleep Efficiency (SE) - by Hour Night 1
Slide 17: Phase 3 - Transient Insomnia PSG Trial Objectives
Objectives Efficacy on sleep onset and sleep duration Design - Phase 3, randomized, controlled, double blind, multicenter, parallel group, sleep laboratory Population - Transient insomnia population using first night effect plus phase advance model in healthy volunteers Dose - Placebo and 6 mg Endpo
Slide 18: Latency to Persistent Sleep (LPS)
PBO 33.6 DXP 6mg 20.6 Phase 3 - Transient Insomnia PSG Trial Primary Endpoint P<0.0001 Latency to Persistent Sleep (LPS) Minutes (mean)
Slide 19: Latency to Sleep Onset (LSO)
PBO 48 DXP 6mg 32 Phase 3 - Transient Insomnia PSG Trial Latency to Sleep Onset (LSO) Minutes (mean) P<0.0001
Slide 20: Wake After Sleep Onset (WASO)
PBO 78 DXP 6mg 38 Phase 3 - Transient Insomnia PSG Trial Wake After Sleep Onset (WASO) Minutes (mean) P<0.0001
Slide 21: Total Sleep Time (TST)
PBO 374 DXP 6mg 425 Phase 3 - Transient Insomnia PSG Trial Total Sleep Time (TST) Minutes (mean) P<0.0001
Slide 22: Subjective Measures
Placebo (N=282) Doxepin 6 mg (N=283) sTST Mean (SD): 394.1 (78.2) 427.2 (47.5) p-value: <0.0001 sWASO Mean (SD): 36.6 (44.4) 26.0 (50.2) p-value: 0.0063 Sleep Quality1 Mean (SD): 0.8 (1.25) 1.2 (1.01) p-value: 0.0004 Phase 3 - Transient Insomnia PSG Trial Subjective Measures 1 7-point Likert scale r
Slide 23: Safety & Tolerability
Phase 3 Trials to Date Safety & Tolerability Well tolerated Overall AE incidence low & comparable to placebo Low discontinuation rate No clinically meaningful next day effects No rebound insomnia, withdrawal effects or tolerance No amnesia, weight gain or anticholinergic effects observed
Slide 24: Positioning
Positioning Targeted by Phase 3 Amnesia Euphoria Hormone Changes Metallic Taste Attributes Sonata Ambien Ambien CR Lunesta Indiplon Rozerem SILENORTM Onset Maintenance ? Last 3rd of Night Long Term Studies ? Not Scheduled Not GABA
Slide 25: SILENOR Development Plan
SILENOR(tm) Development Plan Ph 3 Transient 2005 2006 2007 Ph 3 Adult PSG Ph 1 PK Studies Ph 3 Elderly PSG Ph 3 Elderly Outpatient Submit NDA Pre-Clinical
Slide 26: Nalmefene
Nalmefene Opioid receptor antagonist, marketed in IV form since 1995 for opiate reversal Somaxon product is orally administered Opioid antagonism can reduce urges & cravings
Slide 27: Financial Highlights, 6/30/06
Financial Highlights, 6/30/06 NASDAQ: SOMX Cash, cash equivalents & short term investments Cash burn, YTD 6-30-06 Shares outstanding Fully diluted shares $78.2 mm $25.7 mm 18.0 mm 20.5 mm
Slide 28: Key milestones
Key milestones SILENOR(tm) Phase 3 adult results - Q2 '06 ^ Phase 3 elderly results - late '06 Phase 3 transient results - late '06 ^ Phase 3 elderly outpatient results - late '06 Strategic partnership NDA - Q3 '07 Nalmefene Pilot smoking cessation results - mid '06 ^ Phase 2/3 PG results - early '0
Slide 29: Highlights
Highlights Specialty pharmaceuticals focused on psychiatric and neurologic disorders Three in-licensed product candidates with extensive human experience & established safety records Highly differentiated product profiles addressing large markets, including 2 positive Phase 3 trials in insomnia Comp
Somaxon Pharmaceuticals — Investor Presentation (October 2006) on 6ix